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Cyfip1 haploinsufficiency does not alter GABAA receptor G-subunit expression 37 
and tonic inhibition in PV+ interneurons and dentate gyrus granule cells. 38 
 39 
Abstract 40 
 41 
Copy number variation at chromosomal region 15q11.2 is linked to increased risk of 42 
neurodevelopmental disorders including autism and schizophrenia. A significant gene at this 43 
locus is cytoplasmic fragile X mental retardation protein (FMRP) interacting protein 1 44 
(CYFIP1). CYFIP1 protein interacts with FMRP, whose monogenic absence causes Fragile 45 
X syndrome. FMRP knock-out has been shown to reduce tonic GABAergic inhibition by 46 
interacting with the G-subunit of the GABAA receptor. Using in situ hybridization, qPCR, 47 
western blot techniques and patch clamp electrophysiology in brain slices from a Cyfip1 48 
haploinsufficient mouse, we examined G-subunit mediated tonic inhibition in the dentate 49 
gyrus. In wild-type mice, dentate gyrus granule cells (DGGC) responded to the G-subunit 50 
selective agonist THIP with significantly increased tonic currents. In heterozygous mice, no 51 
significant difference was observed in THIP evoked currents in DGGC. Phasic GABAergic 52 
inhibition in DGGC was also unaltered with no difference in properties of spontaneous 53 
inhibitory post synaptic currents (IPSCs). Additionally, we demonstrate that dentate gyrus 54 
granule cell layer PV+-interneurons (PV+-IN) have functional G-subunit mediated tonic 55 
GABAergic currents which, unlike DGGC, are also modulated by the D1 selective drug 56 
zolpidem. Similar to DGGC, both IPSCs and THIP-evoked currents in PV+-IN were not 57 
different between Cyfip1 heterozygous and wild-type mice. Supporting our 58 
electrophysiological data, we found no significant change in hippocampal G-subunit mRNA 59 
expression or protein level and no change in D1/D4 subunit mRNA expression. Thus, Cyfip1 60 
haploinsufficiency, mimicking human 15q11.2 microdeletion syndrome, does not alter 61 
hippocampal phasic or tonic GABAergic inhibition, substantially differing from the FMRP 62 
knock-out mouse model. 63 
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 64 
Significance Statement 65 
 66 
CYFIP1 is a candidate risk gene for neurodevelopmental and neuropsychiatric disorders.  67 
CYFIP1 protein interacts with FMRP whose loss downregulates tonic GABAergic inhibition 68 
via interaction with the G-subunit of the GABAA receptor. Here, however, we report that 69 
reduced Cyfip1 dosage in mice does not alter tonic GABAergic inhibition in granule cells and 70 
PV+-interneurons of the dentate gyrus, a region rich in G-subunit expression. Despite these 71 
negative findings, our data does demonstrate that PV+-interneurons of the DG granule cell 72 
layer are functionally regulated by tonic GABAergic inhibition, and in contrast to granule 73 
cells, this involves receptors incorporating both G and D1-subunits. Thus, granule cell layer 74 
excitatory neurons and PV+-interneurons may be differentially modulated by subunit 75 
selective GABA receptor targeting drugs.  76 
  77 
Introduction 78 
 79 
Cytoplasmic fragile X mental retardation protein (FMRP) interacting protein 1 (CYFIP1) is a 80 
gene found in the 15q11.2 locus of the human genome (Chai et al., 2003). Copy number 81 
variations (CNVs) at this region, including both microdeletions and microduplications, span 82 
CYFIP1 and three other genes (NIPA1, NIPA2, TUBGCP5) and have been strongly linked by 83 
genomic studies to increased risk of developing neuropsychiatric and neurodevelopmental 84 
disorders including autism spectrum disorder and schizophrenia (Stefansson et al., 2008; 85 
Burnside et al., 2011; Kirov et al., 2012). CYFIP1 has a number of known functions and the 86 
protein it encodes (CYFIP1) interacts with several key signalling complexes. For example, 87 
CYFIP1 is involved in the maturation and maintenance of dendritic complexity and dendritic 88 
spines by supressing the WAVE regulatory complex and regulating actin cytoskeletal 89 
dynamics (Pathania et al., 2014; De Rubeis et al., 2013). Rodent models of Cyfip1 90 
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haploinsufficiency, broadly modelling reduced gene dosage of Cyfip1 in 15q11.2 CNV 91 
carriers, reveal behavioural deficits in the form of altered extinction in inhibitory avoidance, 92 
although wider effects on anxiety and learning were not observed (Bozdagi et al., 2012).     93 
As indicated by its name, CYFIP1 is an important functional partner of the RNA-94 
binding protein FMRP (Schenck et al., 2001; Napoli et al., 2008), which regulates dendritic 95 
targeting of mRNAs (Bassell & Warren, 2008), influences mRNA stability (De Rubeis & 96 
Bagni, 2010) and represses protein translation of ~800 neuronal mRNA ‘FMRP targets’ (Hou 97 
et al, 2006; Darnell et al., 2001). The transcriptional silencing of the FMRP gene FMR1 98 
causes Fragile X syndrome (FXS), which is characterised by a range of physical, 99 
behavioural and cognitive deficits (Garber et al., 2008) and is the leading monogenic cause 100 
of autism and intellectual disability (Santoro et al., 2012).  101 
In comparison to CYFIP1, the molecular pathways disrupted by FMRP loss have 102 
been more extensively characterised. One significant effect of FMRP loss is disruption of 103 
GABAergic signalling across brain regions including the hippocampus, cortex and amygdala 104 
(Paluszkiewicz et al., 2011; Braat et al., 2015). FMRP is expressed in GABAergic 105 
interneurons throughout development suggesting an important role in interneuron maturation 106 
and function (Feng et al., 1997) and a subset of GABAergic signalling mRNAs appear to be 107 
under the regulation of FMRP (El Idrissi et al., 2005; Darnell et al., 2011). Fmr1 KO animal 108 
studies have revealed that FMRP loss produces significant pre- and postsynaptic effects on 109 
GABAergic signalling. Changes in the level of the GABA synthesising enzyme glutamatic 110 
acid decarboxylase (GAD65/67), the GABA transporter 1 (GAT1) and enzymes responsible 111 
for GABA breakdown (GABA-T and SSADH) have all been associated with loss of FMRP 112 
(Martin and Huntsman, 2014). Postsynaptically, decreased mRNA expression and/or protein 113 
levels for at least 8 GABAA receptor (GABAAR) subunits (D1, D3, D4, E1, E2, J1, J2, and G) have 114 
been described in amygdala, cortex and hippocampus (Braat et al., 2015; Sabanov et al., 115 
2017; Zhang et al., 2017).  116 
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In particular, deficits in tonic GABAergic inhibition have been implicated. FMRP has 117 
been shown to bind to the GABAAR G-subunit (Miyashiro et al., 2003; Dichtenberg et al., 118 
2008) and FMRP knock-out reduces G-subunit mRNA and protein expression in the 119 
amygdala, cerebellum, cortex and dentate gyrus of a mouse model of FXS (D’Hulst et al., 120 
2006; Curia et al., 2009; Braat et al., 2015; Zhang et al., 2017). Moreover, the GABAAR G-121 
subunit selective agonist THIP and the neurosteroid ganaxolone ameliorate symptoms in a 122 
mouse model of FXS (Olmos-Serrano et al., 2011; Braat et al., 2015). Importantly, the G-123 
subunit is exclusively found in extrasynaptic GABAA receptors (eGABAARs) and mediates 124 
tonic inhibition across brain regions, although in the hippocampus it is almost exclusively 125 
expressed in the dentate gyrus (Milenkovic et al., 2013; Zheng et al., 2009; Pirker et al., 126 
2000). Thus, the current view is that disrupted tonic GABAergic inhibition may be a major 127 
contributing in FXS and that modulation of GABAergic signalling is a potential route for 128 
therapeutic intervention in this disorder (Braat et al., 2015, 2017). 129 
 Therefore, due to the association of CYFIP1 with neuropsychiatric disorders, its 130 
known interaction with FMRP and the effects of FMRP on GABA signalling, we have used a 131 
Cyfip1 haploinsufficient mouse to explore the effects of Cyfip1 on GABAergic inhibition. We 132 
find that, unlike FMRP loss, Cyfip1 haploinsufficiency does not reduce GABAAR G-subunit 133 
expression in the hippocampus. Electrophysiological experiments show that neither phasic 134 
inhibitory postsynaptic currents (IPSCs) nor tonic GABAergic inhibition is changed in dentate 135 
gyrus granule cells (DGGC) or granule cell layer (GCL) parvalbumin positive (PV+-IN) 136 
interneurons. Thus, in mouse hippocampus, haploinsufficiency of Cyfip1 does not disrupt 137 
GABAergic signalling in a similar manner to FMRP knock-out. Nonetheless, our findings 138 
reveal that GCL PV+-IN do, as previously suggested (Milenkovic et al., 2013), express 139 
functional eGABAARs containing G-subunits that contribute to tonic inhibition in these cells. 140 
Unlike DGGC (Nusser and Mody, 2002), a fraction of the tonic current in granule cell layer 141 
PV+-IN is modulated by the D1 selective ligand zolpidem suggesting these cells may express 142 
D1 subunit containing eGABAARs.  143 
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 144 
  145 
Materials and Methods 146 
 147 
Animals  148 
Experiments involving recordings from dentate gyrus granule cells were performed on Cyfip1 149 
heterozygous (Cyfip1+/-) and wild-type (WT) mice. The Cyfip1 mouse line (Allele: 150 
Cyfip1tm2a(EUCOMM)Wtsi ) was generated using the ‘Knockout-first’ strategy by the Wellcome 151 
Trust Sanger Institute as part of the International Knockout Mouse Consortium (IKMC) on 152 
the C57BL/6N Taconic background. We obtained pairs of breeding mice (B6NTac;B6N-153 
Atm1Brd Cyfip1tm2a(EUCOMM)Wtsi/WtsiH) from the EMMA mouse repository (Infrafrontier Mouse 154 
Disease Models, RRID: IMSR_EM:06868). Experimental animals were generated by 155 
crossing male Cyfip1+/- mice with wild-type female C57BL/6J mice (RRID: 156 
IMSR_JAX:000664), generating hybrid C57BL/6J/6N Cyfip1+/- and WT littermates. Animals 157 
were genotyped following the procedure recommended by the Sanger Institute. For 158 
experiments involving recordings from parvalbumin positive (PV+) interneurons in the 159 
dentate gyrus granule cell layer we crossed a PV-Cre knock-in mouse (B6;129P2-160 
Pvalbtm1(cre)Arbr/J, RRID: IMSR_JAX:008069) with a Cre-dependent tdTomato reporter mouse 161 
(B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J, RRID: IMSR_JAX:007914) to drive expression of 162 
the red fluorescent protein tdTomato in PV+ cells. These animals were then subsequently 163 
crossed with Cyfip1+/- mice to produce PV+TdCyfip1WT/+/- mice. Electrophysiological 164 
experiments and protein and mRNA expression experiments were performed on adolescent 165 
(5-7 weeks old) or adult (3.5-6 months old) mice. All protein and mRNA expression work was 166 
conducted on behaviourally naïve, adult male 6J/6N hybrid mice and further molecular work 167 
was performed on behaviourally naïve adolescent male 6J/6N mice. All animal procedures 168 
were performed in accordance with the [Author University] animal care committee’s 169 
regulations. 170 
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 171 
In situ hybridization, qPCR and Western blot analysis 172 
For all molecular work, mice were sacrificed by carbon dioxide inhalation and whole brains 173 
were extracted. For in situ hybridisation (ISH), whole brains were snap-frozen and stored at -174 
80˚C, whilst for quantitative real-time PCR (qRT-PCR) and protein immunoblotting by 175 
western blot, the whole hippocampus from both brain hemispheres were dissected free-hand 176 
and frozen on dry ice before storage at -80°C.  177 
 178 
In situ hybridization 179 
Coronal brain sections (14 μm) were cut using a cryostat (-20˚C, Leica Microsystems) and 180 
mounted on poly-L-lysine coated glass slides. Each slide consisted of 1 slice from 6 181 
separate brains, matched for hippocampal region (Paxinos & Franklin, 2004) and 182 
counterbalanced across genotype. Two series of the dorsal hippocampus were produced 183 
representing all experimental animals (n = 6 per genotype). Slides were fixed in 4% PFA 184 
solution, followed by dehydration in ethanol and stored in 95% EtOH at 4˚C until required. 185 
Slides were processed in parallel as an internal technical control. 186 
The protocol for semi-quantitative ISH using a 3’-end radiolabelled oligonucleotide 187 
(45mer) with [ɑ-35S]dATP was broadly similar to previous work (Clifton et al., 2017; Kirtley et 188 
al., 2010). Briefly, an oligonucleotide probe for mouse Gabrd was bioinformatically designed 189 
(NM_008072.2, FASTA, NCBI) to contain 45 base-pairs, a 50% AT:CG ratio, contain no 190 
more than 3 consecutive matching bases and detect all known Gabrd mouse transcripts 191 
(NCBI and Ensembl). The Gabrd probe sequence (3’-5’) was: TCCAT GTCAC AGGCC 192 
ACTGT GGAGG TGATG CGGAT GCTGT ATAAA, binding to the complementary murine 193 
Gabrd nucleotide sequence (nucleotide position 607-563).  194 
The Gabrd probe was commercially synthesised (Sigma-Aldrich) and diluted in 195 
phosphate buffer (1 μg/μl, pH7) and further diluted to a working concentration of 5 ng/μl (in 196 
sterile water). Gabrd oligonucleotide probe (1 μl) was added to 6.5 μl deionized water, 2.5 μl 197 
terminal deoxynucleotidyl transferase buffer (Promega), 1 μl terminal deoxynucleotidyl 198 
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transferase (Promega) and 1 μl deoxyadenosine 5’- (α-thio) triphosphate [35S] (dATP) 199 
(Perkin Elmer), before being incubated at 30˚C for 1 hr for 3’-end nucleotide labelling. After 200 
incubation, the labelled nucleotide went through clean-up via Qiaquick Nucleotide Removal 201 
Kits (Qiagen, as per manufacturer’s protocol) and 2 ul DTT (1M) was added to the eluted 202 
oligonucleotide. Activity of labelled Gabrd probe was measured (HIDEX Triathler liquid 203 
scintillation counter) and within a range of 60,000 - 250,000 CPM/μl. 204 
Three consecutive slides of brain sections (per series) were selected for ISH, with 2 205 
slides used to define ‘Total Specific’ (TS) hybridisation levels (i.e. technical repeat included) 206 
and 1 slide to define the ‘Non-Specific’ (NS) hybridisation signal. Radiolabelled probes were 207 
applied at a level of 200,000 cpm per slide. A master mix for the Gabrd probe was made 208 
including radiolabelled probe, 2 μl of Dithiothreitol (DTT, 1 M) and 100 μl Hybridisation buffer 209 
(HYB) per slide (see Wisden & Morris 1994, for further details on HYB). This master mix 210 
solution was applied to 2 TS slides per series (100 μl/slide), and then unlabelled probe was 211 
added to the remaining master mix (8:1 ratio of unlabelled/labelled probe) and this was 212 
subsequently added to NS allocated slides (100 μl). Parafilm strips were used to form the 213 
necessary matrix for ISH to occur, whilst all slides were sealed in humidified plastic 214 
chambers and incubated at 42˚C overnight. Parafilm coverslips were subsequently removed 215 
in 1 x SSC at RT. Slides were then washed in 1 x SSC at 52˚c for 1 hr, rinsed in 0.1 x SSC 216 
and dehydrated in ethanol.   217 
As per Kirtley & Thomas 2010, autoradiographs were generated using radiographic 218 
film exposed to a quantitative C14 ladder and TS/NS slides for 7 days and developed. 219 
Autoradiograph densitometry was performed (ImageJ) blind to genotype, whereby NS values 220 
were subtracted from TS values to provide a Specific activity value, providing a measure of 221 
mRNA expression.   222 
 223 
qRT-PCR 224 
RNA was extracted from dissected whole hippocampus using RNeasy Kits (Qiagen), 225 
followed by DNase treatment of RNA (TURBO DNA-free Kit, Thermo Fisher Scientific) and 226 
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converted to cDNA (RNA to cDNA EcoDry Premix, Random Hexamers, Clontech, Takara). 227 
cDNA samples were prepared in triplicate in 96-well reaction plates for SYBR-green-based 228 
quantitative real-time PCR (SensiFAST, HI-ROX, Bioline), according to manufacturer’s 229 
instructions, using a StepOnePlus System (Applied Biosystems, Thermo Fisher Scientific). 230 
Gabrd-specific primers, alongside Gapdh and Hprt primers (housekeeping genes), were 231 
bioinformatically designed to span at least one exon-exon boundary and to match only for its 232 
target mRNA sequence in mouse (primer-BLAST and nBLAST, NCBI), before being 233 
commercially synthesised (Sigma-Aldrich). Primer efficiencies were experimentally 234 
determined through a dilution series of experimentally separate wildtype mouse hippocampal 235 
cDNA (efficiency of 90-110% was required, annealing temperature set at 60°C). All samples 236 
were run in triplicate and individual ΔCt values (relative to Gapdh and Hprt) were used to 237 
quantify mRNA gene expression. Primers used for qRT-PCR were as follows: Gabrd (FOR: 238 
GGGCAGAGATGGATGTGAGG, REV: CTTGACGACGGGAGATAGCC; targeting exon 8-239 
9); Gapdh (FOR: GAACATCATCCCTGCATCCA, REV: CCAGTGAGCTTCCCGTTCA); Hprt 240 
(FOR: TTGCTCGAGATGTCATGAAGGA, REV: AATGTAATCCAGCAGGTCAGCAA).  241 
 242 
Immunoblotting by western blot 243 
Hippocampal tissue was homogenized manually with a glass Dounce homogeniser in 1ml of 244 
ice-cold lysis RIPA buffer (Thermo Fisher Scientific) containing protease inhibitors (cOmplete 245 
Mini EDTA-free Protease Inhibitor, Roche, Sigma-Aldrich, 1 tablet/10ml RIPA). The 246 
homogenates were centrifuged at 12,000 rpm for 20 minutes at 4°C and aliquots of 247 
supernatant containing proteins stored at -80°C. Total protein was quantified using Pierce 248 
BCA Protein Kit Assay, as per manufacturer’s instructions (Thermo Fisher Scientific) and a 249 
1:1 ratio of 40μg of protein sample was added to 2 x Laemmli sample buffer (containing 1/20 250 
β-mercaptoethanol, Bio-rad). Samples were denatured at 95°C for 5 min, loaded 251 
alternatively by genotype and separated on a 4-12% gradient Bis-Tris Midi gel (NuPAGE, 252 
Thermo Fisher Scientific) in 1x Bolt MES SDS Running Buffer (Thermo Fisher Scientific) at a 253 
constant voltage of 115 V for 1 hr. Transfer was performed in 1x Bolt Transfer Buffer 254 
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(Thermo Fisher Scientific) to Amersham Protran nitrocellulose membranes (GE Healthcare 255 
Life Sciences) at a constant voltage of 85 V for 2 hr 15 min at 4°C.  256 
Blots were blocked in 5% non-fat milk (Amersham ECL Blocking Agent, GE 257 
Healthcare Life Sciences) in 0.1 M Tris buffered saline solution containing 0.2% Tween 20 258 
(TBST), and this TBST solution was used for all subsequent washes. Primary and 259 
fluorescent secondary antibodies were similarly diluted in TBST containing 0.2% Tween 20 260 
and 5% milk and they were used at the following concentrations: GABA-A R G (Novus 261 
Biologicals, RRID: AB_2107256), 1:500; Calnexin (Abcam, RRID: AB_2069006), 1:5,000 262 
and IRDye® 680RD Goat anti-Rabbit IgG (Li-Cor, RRID: AB_10956166), 1:15,000. 263 
Incubation of blots in primary antibody solutions were performed at 4°C overnight, whilst 264 
fluorescent secondary antibodies were for 1 hr at RT. Blots were visualised using the 700nm 265 
channel of the Odyssey CLx Imaging System (Li-Cor) and densitometric quantification was 266 
performed on scanned blot films using ImageStudio Lite software (Li-Cor). The raw 267 
fluorescent signal of each GABA-A R G band per sample was divided by its own protein 268 
loading control, calnexin (with background subtraction). The WTs on the entire blot were 269 
then averaged together and normalised to 100%, whilst across-blot variance was minimised 270 
by giving each individual Cyfip1+/- signal relative to the averaged total of all WT lanes.  271 
 272 
Brain slice preparation and electrophysiology 273 
Animals of either sex were deeply anaesthetised using isoflurane, decapitated and their 274 
brains removed into chilled (1-3°C) cutting solution containing (in mM) 60 sucrose, 85 Nacl, 275 
2.5 KCl, 1 CaCl2, 2 MgCl2, 1.25 NaH2PO4, 25 NaHCO3, 25 D-glucose, 3 kynurenic acid, 276 
0.045 indomethacin. Horizontal hippocampal brain slices (300 Pm) containing the dentate 277 
gyrus were prepared from adolescent and adult wild-type and heterozygous Cyfip1 and 278 
PV+TdCyfip1 mice, stored for 20 minutes at 35°C in sucrose-containing solution and 279 
subsequently maintained at room temperature in artificial CSF (aCSF) containing (in mM) 280 
125 NaCl, 2.5 KCl, 1 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 25 NaHCO3, 25 D-glucose (305 281 
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mOSm) then used within 4-6 hours. For recording, slices were transferred to a submersion 282 
chamber continuously perfused with warmed (33-34°C) aCSF containing (in mM) 125 NaCl, 283 
2.5 KCl, 2 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 25 NaHCO3, 25 D-glucose, 3 kynurenic acid (305-284 
10 mOSm, pH 7.4) at a flow rate of 3 ml.min-1. Electrophysiological recordings were 285 
performed on dentate gyrus granule cells (DGGC) and PV+-interneurons (PV+-IN) of the 286 
dentate gyrus granule cell layer. DGGC were identified using Dodt-contrast video 287 
microscopy and PV+-IN were identified by their expression of the red fluorescent protein 288 
tdTomato following 2-photon excitation at O = 900 nm (Prairie Ultima 2-photon microscope, 289 
Bruker). Whole-cell voltage clamp recordings were made using a Multiclamp 700B 290 
(Molecular Devices) patch clamp amplifier with patch pipettes with resistances between 3-6 291 
M: when filled with an internal recording solution containing (in mM) 130 CsCl, 2 MgCl2, 4 292 
Mg-ATP, 0.3 Na-GTP, 10 HEPES, 0.1 EGTA (295 mOsm, pH 7.3) supplemented with Alexa 293 
Fluor 594 (DGGC, 50 PM, Life Technologies) or Alexa Fluor 488 (PV+-IN, 100 PM, Life 294 
Technologies). All experiments were performed at a holding potential (Vh) of -70 mV unless 295 
specifically indicated elsewhere. Series resistance (RS) was compensated by 80% and cells 296 
showing changes of RS greater than 20% over the course of the experiment were rejected.  297 
Data were sampled at 20 kHz and low-pass filtered at 6 kHz. 4,5,6,7-298 
tetrahydroisoxazolopyridin-3-ol (THIP, Gaboxadol), 1,2,5,6-Tetrahydro-1-[2-299 
[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid hydrochloride (NNC711, 300 
NO711), N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide (Zolpidem) 301 
and picrotoxin were obtained from Tocris Bio-techne. 302 
 303 
Data analysis and statistics 304 
Spontaneous IPSCs were detected using a template search routine in pClamp 10 (Clampex, 305 
Molecular Devices) and their amplitude, frequency and integral were measured. IPSCs were 306 
automatically detected from a 20 - 60 second control baseline period and manually 307 
inspected post-hoc for false event detection. For analysis of event frequency the simple 308 
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mean arithmetic IPSC frequency for each cell was calculated as the number of IPSCs 309 
detected divided by the length of the sampling period. The instantaneous frequency was 310 
calculated as 1 / inter-IPSC interval of all recorded IPSCs. Occasional unclamped action 311 
currents were detected and these were rejected from analysis. For analysis of IPSC decay, 312 
events whose decay phase were contaminated by other IPSCs were rejected and remaining 313 
events were averaged to produce a single averaged IPSC for each cell. Each averaged 314 
IPSC was fitted with a double exponential function with two amplitude components (A and B) 315 
and two decay time constants (W1 and W2) to calculate the weighted decay time-constant (WW) 316 
by WW = [(A/A+B) W1] + [(B/B+A) W2]. The mean charge carried by individual IPSCs (in pC) for 317 
each cell was the integral of the averaged IPSC calculated by multiplying the amplitude of 318 
the averaged IPSC for each cell by its WW. The total IPSC charge delivered was the mean 319 
IPSC charge multiplied by the arithmetic IPSC frequency. To measure tonic GABAA currents 320 
the mean holding current at Vh -70 mV in the absence and presence of drugs was measured 321 
by fitting a single Gaussian function to all-points histograms constructed from five one 322 
second long sampling periods (Bright and Smart, 2013) (Fig. 2). The holding current for each 323 
condition was measured as the mean of the Gaussian distribution and the root mean square 324 
(RMS) noise was the standard deviation of the distribution. To account for the hierarchical 325 
structure of the data and non-independencies within it (see Results and Fig. 1E), the 326 
amplitudes and instantaneous frequencies of IPSCs in DGGC and PV+-IN were analysed 327 
using a linear mixed effects (LME) model constructed in the open-source statistical software 328 
environment R (R Core Team, 2018) using the lme4 module (Bates et al., 2015). The model 329 
used for the analysis was a random intercept model including a single fixed effect (genotype: 330 
WT vs Cyfip1+/-) and two random effects accounting for variation between cells and between 331 
mice. The linearity and homoskedasticity of the data was confirmed by plotting the residuals 332 
obtained from the fitted model. Data obtained for both IPSC amplitudes and instantaneous 333 
frequencies we found to follow lognormal distributions. LME models were therefore fit to the 334 
natural logarithm [g(x) = ln(x), x>0] transformed IPSC amplitude and instantaneous 335 
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frequency data which followed approximately normal distributions (see Fig.1 and Fig.3). 336 
Subsequently, mean (P) IPSC amplitude (in pA) and frequency (in Hz) for each genotype 337 
were obtained by inverting the intercept values obtained from the LME models (fitted to log-338 
transformed data) using the exponential function [g-1(P) = eP]. Thus, the mean values 339 
reported for IPSC amplitude and instantaneous frequency are the geometric rather than 340 
arithmetic means of the data. The geometric mean of the log-normally distributed data 341 
represents the ‘central tendency’ of the data better than the arithmetic mean and gives a 342 
more accurate measure of the typical event without the distorting effect of the relatively small 343 
number of large amplitudes or high instantaneous frequencies IPSCs that skew the 344 
distribution. The geometric mean IPSC amplitudes and instantaneous frequencies obtained 345 
using this approach are reported with their 95% confidence intervals which are asymmetric 346 
around the mean. Upper and lower confidence limits were calculated as the exponential 347 
[g(CI) = eCI] of the mean plus or minus 1.96 times the standard error of the intercept vales 348 
obtained from the LME model fits. The effect of genotype on IPSC amplitude/frequency was 349 
tested using the ‘anova()’ function in R (likelihood ratio test) to compare our model with a null 350 
model which excluded the fixed effect. Unless otherwise indicated, n refers to the number of 351 
cells recorded under each condition. For each condition cells were sampled from a minimum 352 
of 3 different non-littermate mice for each genotype. Data analysis was performed using 353 
pClamp 10 (Molecular Devices), Prism 5 (Graphpad) software and R (https://www.R-354 
project.org/). Statistical testing was by paired/unpaired t-test or one-way ANOVA where 355 
appropriate and as indicated in text.  356 
For ISH, qRT-PCR and immunoblotting techniques, outliers > 2.5 SD from the mean 357 
were removed and significance was determined by one-way or two-way ANOVA using SPSS 358 
software (IBM, v.20). Post hoc Dunnett’s multiple comparison procedure was applied to data 359 
which surpassed significance threshold (alpha = 0.05) in ANOVA, to determine specific 360 
group differences. Detailed statistical analyses can be found in the figure legends. All values 361 
are given as mean ± SEM, with the exception of qRT-PCR data given as mean ± SD. 362 
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 363 
Results 364 
 365 
GABAergic inhibition is unaltered in dentate gyrus granule cells of Cyfip1+/- mice 366 
We performed whole-cell voltage clamp recordings from dentate gyrus granule cells (DGGC) 367 
to determine the effects of Cyfip1 haploinsufficiency on GABAergic inhibition. To confirm that 368 
all DGGC we recorded from were fully mature neurons, and not from immature adult born 369 
granule cells, we first performed current clamp recordings on a subset (n = 4) of DGGC. This 370 
revealed, as shown previously, that cells with mature morphology and dendrites projecting 371 
into the outer molecular layer (Fig. 1A) also displayed firing properties and input resistances 372 
characteristic of mature cells (< 300M:) (Fig. 1B). Thus, in subsequent voltage clamp 373 
experiments, we considered recorded cells to be fully mature granule cells based upon 374 
inspection of their morphology after filling with Alexa Fluor 594. First, we measured 375 
properties of synaptic inhibition in DGGCs by recording spontaneous inhibitory postsynaptic 376 
currents (sIPSCs). In control cells, from wildtype (WT) mice, our recordings revealed that 377 
sIPSCs properties were similar to those reported for DGGC in previous studies, consistent 378 
with a large proportion of their inhibitory input coming from local fast-spiking interneurons 379 
(Fig. 1C) (Bartos et al., 2001; Nusser and Mody, 2002; Chandra et al., 2006). First we 380 
analysed the effect of genotype on IPSC amplitudes in DGGCs. We found that the 381 
amplitudes of sampled IPSCs in both WT and Cyfip1+/- DGGC were approximately log-382 
normally distributed (Fig. 1E). Thus, for subsequent analysis we used the corresponding log-383 
transformed data which followed a normal distribution (Fig. 1F). Since many individual IPSCs 384 
were recorded from each neuron (i.e. repeated measures) and several neurons recorded 385 
from individual mice (Figure 1E and F) it is clear our data violates the critical assumption of 386 
independence required for linear modelling. Therefore, we chose to fit the log-transformed 387 
IPSC amplitudes, pooled from all recorded DGGC (WT: 9494 IPSCs from 25 cells / 5 mice, 388 
Cyfip1+/-: 4948 IPSCs from 14 cells / 4 mice), using a linear mixed effects (LME) model. 389 
Using LME models allows us to analyse the effects of genotype across our entire sample of 390 
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IPSCs while accounting for the non-independencies that result from the hierarchical 391 
structure of our data. An example of the hierarchical structure within the data can be seen in 392 
in the scatterplot shown in Figure 1E which shows individual IPSCs grouped by neuron, by 393 
mouse and by genotype. In our analysis, the LME models we have used account for the 394 
random variation across individual neurons and individual mice allowing us to isolate the 395 
effect of genotype on the dependent variable (IPSC amplitude/frequency). Using this 396 
approach we found that genotype did not significantly affect the amplitude of IPSCs in 397 
DGGC (F2(1) = 0.06, p = 0.80) with WT IPSCs having a mean amplitude of 25.7 pA (95% CI: 398 
21.1, 31.2) and Cyfip1+/- IPSCs having an amplitude of 26.3 pA (95% CI: 22.6, 30.6). 399 
Moreover, we found no significant differences in the weighted decay time-constant (WW) (p = 400 
0.70, unpaired t-test) (Table 1) (Fig. 1C,D) and charge transfer (p = 0.95, unpaired t-test) 401 
(Table 1) for averaged IPSCs between Cyfip1+/- mice and their WT counterparts. Similarly, 402 
we also found that the instantaneous frequencies (1 / inter-IPSC interval) of both WT and 403 
Cyfip1+/- IPSCs were log-normally distributed (Fig. 1G) and that their corresponding log-404 
transformed values were normally distributed (Fig. 1H). Fitting an LME model revealed that 405 
genotype had no significant effect on IPSC instantaneous frequency (F2(1) = 0.67, p = 0.41) 406 
with WT IPSCs having a mean frequency of 7.42 Hz (95% CI: 6.44, 8.55) and Cyfip1+/- 407 
IPSCs having a frequency of 6.86 Hz (95% CI: 5.74, 8.18) respectively. Thus, we find that 408 
haploinsufficiency of Cyfip1 does not impair phasic GABAergic inhibition in DGGC of the 409 
mouse hippocampus.  410 
 However, as discussed earlier, FMRP can reduce tonic inhibition through 411 
mechanisms that are not dependent upon changes in presynaptic neurotransmitter release, 412 
in particular, a direct postsynaptic reduction of the expression of GABAA receptor G-subunits 413 
(D’Hulst et al., 2006; Curia et al., 2009; Zhang et al., 2017). To test whether the loss of one 414 
Cyfip1 allele and reduction in expression of the FMRP binding partner CYFIP1, which 415 
mimics microdeletion at locus 15q11.2 in humans, produces a similar reduction in GABAA 416 
receptor G-subunit dependent tonic inhibition as observed in FXS, we evoked currents using 417 
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the G-subunit selective drug THIP (Gaboxadol). We measured THIP evoked currents using 418 
both the drug-induced shift in holding current and difference in RMS-noise as the latter has 419 
been suggested to be more sensitive to detecting small differences in tonic inhibition (Bright 420 
and Smart, 2013). To evoke sufficiently large currents to allow us to easily compare between 421 
genotypes we used THIP at concentrations of 3 and 10 PM. At 3 PM, THIP is largely 422 
selective for high affintity G-subunit containing receptors whereas at 10 PM it may also 423 
substantially activate G-subunit lacking receptors (i.e. DE pentamers) (Meera et al., 2011). 424 
This approach allowed us to investigate differences in both of the potential pools of 425 
extrasynaptic receptors in these cells across genotypes. In DGGC cells from WT animals, 426 
bath application of THIP produced a concentration dependent increase in the current 427 
required to hold the cell at -70 mV ('ITHIP) (WT: 'ITHIP 3PM: 54.8 ± 4.4 pA, n = 7; 'ITHIP 10PM: 428 
102.5 ± 5.6 pA, n = 15) (Fig. 2A,C) and a corresponding increase in RMS-noise (WT: 429 
RMScontrol: 4.24 ± 0.15 pA, n = 15; RMSTHIP 3PM: 8.39 ± 0.35 pA, n = 7; RMSTHIP 10PM: 11.81 ± 430 
0.33 pA, n = 15) (Fig. 2A,E) indicating increased opening of G-subunit containing 431 
extrasynaptic GABAA receptors. The THIP evoked currents were completely blocked by the 432 
GABAA channel blocker picrotoxin (PTX, 100 PM) confirming their GABAergic nature (Fig. 433 
2A). We observed a very slight, but not significant, reduction in both the magnitude of 'ITHIP 434 
(Cyfip1+/-: 'ITHIP 3PM: 50.6 ± 2.5 pA, n = 10, p = 0.39, 'ITHIP 10PM: 90.0 ± 5.3 pA, n = 10, p = 435 
0.14, unpaired t-test) (Fig. 2B,C) and RMS noise (Cyfip1+/-: RMScontrol: 4.25 ± 0.14 pA, n = 436 
10, p = 0.96; RMSTHIP 3PM: 7.90 ± 0.31 pA, n = 10, p = 0.31; RMSTHIP 10PM: 11.06 ± 0.52 pA, n 437 
= 10, p = 0.21) (Fig. 2B,E) in Cyfip1+/- compared to WT DGGC. To confirm that the lack of 438 
observed difference in 'ITHIP was not due to a compensatory change resulting from a 439 
genotype dependent change in dendritic size or complexity we normalised the evoked 440 
currents per pF of membrane capacitance (Cm). Although we observed no significant (p = 441 
0.47, unpaired t-test) difference in Cm between WT (9.4 ± 0.4 pF, n = 15) and Cyfip1+/- (10.0 442 
± 0.8 pF, n = 10) DGGC (Fig. 2D), normalisation of 'ITHIP to Cm revealed a trend towards a 443 
reduction in THIP evoked currents in Cyfip1+/-  DGGC ('ITHIP 3PM: 5.2 ± 0.2 pA/pF, n = 10; 444 
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'ITHIP 10PM: 9.3 ± 0.6 pA/pF, n = 10) compared to WT DGGC ('ITHIP 3PM: 6.2 ± 0.2 pA/pF, n 445 
= 7, p = 0.01;  'ITHIP 10PM: 11.0 ± 0.5 pA/pF, n = 15, p = 0.06) (Fig. 2F), although the 446 
difference was small and only statistically significant for the lower concentration of THIP. 447 
Finally, to determine whether changes in tonic inhibition might occur later in life, we 448 
performed recordings from a small number of adult WT and Cyfip1+/- mice (n = 2 mice per 449 
genotype). Similarly to the findings in adolescent mice, we found currents evoked by 3 PM 450 
THIP were not significantly different between genotypes in DGGC of older mice (WT: 'ITHIP 451 
3PM: 62.9 ± 5.9 pA, n = 9; Cyfip1+/-: 'ITHIP 3PM: 70.3 ± 7.1 pA, n = 9, p = 0.44, unpaired t-452 
test). Thus, overall we conclude that haploinsufficiency of Cyfip1 does not significantly alter 453 
GABAergic inhibition in DGGC of the mouse hippocampus. 454 
 455 
GABAergic inhibition is unaltered in granule cell layer PV+ interneurons of Cyfip1+/- mice 456 
As well as DGGC, detailed immunohistochemical studies have identified that interneurons of 457 
the dentate gyrus also express GABAAR G-subunits. In particular, PV+-interneurons (PV+-IN) 458 
found in the granule cell layer (GCL) and subgranular zone (SGZ) of the dentate gyrus have 459 
100% co-expression of parvalbumin and GABAAR G-subunits (Milenkovic et al., 2013). 460 
However, it remains to be demonstrated that PV+-IN in these layers express functional G-461 
subunit dependent tonic GABAergic currents. Since PV+ interneurons have been previously 462 
implicated as key targets in neuropsychiatric disorders we tested for the functional presence 463 
of extrasynaptic GABAergic inhibition in these cells in Cyfip1+/- and WT mice. To do this we 464 
crossed a PV+-Cre mouse with a tdTomato reporter mouse line and subsequently the 465 
Cyfip1+/- mouse (PV+TdCyfip1) and made targeted patch clamp recordings from GCL PV+-IN 466 
(Fig. 3A). Current-clamp recordings from GCL PV-INs (n = 3) showed that these PV+ cells 467 
had firing properties, typical of fast-spiking basket cells including high frequency firing and 468 
action potentials with characteristic short half-widths (Fig. 3B). First, we compared phasic 469 
GABAergic inhibition in GCL PV+-IN in Cyfip1+/- and WT mice. Consistent with previous 470 
studies, IPSCs in PV+-IN decayed more rapidly than those recorded in DGGC with 471 
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significantly shorter decay time-constants (WW) (WT: DGGC: 4.4 ± 0.1 ms, n = 25, WT: PV+-472 
IN: PV+-IN 1.8 ± 0.2 ms, n = 18, p < 0.0001, unpaired t-test) (Table 1 and Figure 3C,D). This 473 
can be seen clearly in the overlaid traces shown in Figure 3C/D and is consistent with a 474 
higher level of expression of D1 subunits in PV+-IN compared to DGGC (Bartos et al., 2001; 475 
2002). Similarly to DGGCs, IPSC amplitudes (Fig. 3E) and instantaneous frequencies (Fig. 476 
3G) in PV+-IN were found to be log-normally distributed. Therefore, we fit LME models to the 477 
log-transformed data values, which were approximately normally distributed (Fig. 3F,H), in 478 
order to account for the hierarchical structure of the data as depicted in the scatterplots in 479 
Figure 3F and H. As for DGCGs, we found that genotype had no effect upon IPSC 480 
amplitudes in PV+-IN (F2(1) = 0.03, p = 0.86) with WT IPSCs (n = 14358 IPSCs from 18 cells 481 
/ 5 mice) having a mean amplitude of 39.3 pA (95% CI: 30.3, 50.9) and Cyfip1+/- IPSCs (n = 482 
6881 IPSCs from 13 cells / 4 mice) having a mean amplitude of 40.2 pA (95% CI: 33.0, 483 
49.0). We also found no significant difference in the weighted decay time-constant (WW) (p = 484 
0.32, unpaired t-test) (Table 1 and Fig. 3C,D) and charge transfer (p = 0.73, unpaired t-test) 485 
(Table 1) for IPSCs between Cyfip1+/- mice and WT littermates. In comparison to DGGC, 486 
PV+-INs had an approximately 4 fold higher arithmetic mean IPSC frequency (Table 1 and 487 
Figure 3C,F). Fitting an LME model to the log-transformed PV+-IN IPSC instantaneous 488 
frequency data revealed a mean WT IPSC instantaneous frequency of 32.1 Hz (95% CI: 489 
25.1, 41.0) compared to a mean Cyfip1+/- IPSC frequency of 35.9 Hz (95% CI: 29.9, 43.3). 490 
Genotype did not significantly (F2(1) = 0.81, p = 0.37) affect IPSC instantaneous frequency in 491 
PV+-IN. Thus, as with DGGC, we conclude that Cyfip1 haploinsufficency does not change 492 
the properties of IPSCs in PV+-IN of the dentate gyrus. 493 
Unlike DGGCs, it remains to be demonstrated if PV-INs in the GCL of the DG 494 
express functional G-subunit containing extrasynaptic GABAARs and have tonic GABAergic 495 
inhibition. Therefore, we next used THIP to demonstrate the presence of these receptors in 496 
molecularly identified GCL PV+-IN and to compare their relative activation in Cyfip1+/- and 497 
WT cells. In WT PV+-IN, THIP produced a concentration dependent picrotoxin-sensitive 498 
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increase in holding current (WT: 'ITHIP 3PM: 58.5 ± 11.9 pA, n = 6; 'ITHIP 10PM: 161.6 ± 27.2 499 
pA, n = 6) (Fig. 4A,C) that was accompanied by a marked increase in RMS-noise (WT: 500 
RMScontrol: 6.92 ± 0.36 pA, n = 6; RMSTHIP 3PM: 10.33 ± 1.29 pA, n = 6; RMSTHIP 10PM: 13.15 ± 501 
1.66 pA, n = 6) (Fig. 4A,E) demonstrating the presence of G-subunit containing extrasynaptic 502 
GABAARs. However, we found no significant difference in the magnitude of THIP evoked 503 
currents (Cyfip1+/-: 'ITHIP 3PM: 56.6 ± 7.6 pA, n = 8, p = 0.71; 'ITHIP 10PM: 174.2 ± 19.9 pA, n 504 
= 8, p = 0.89, unpaired t-test) or changes in RMS-noise (Cyfip1+/-: RMScontrol: 7.44 ± 0.30 pA, 505 
n = 8, p = 0.29; RMSTHIP 3PM: 10.94 ± 0.55 pA, n = 8, p = 0.64; RMSTHIP 10PM: 15.09 ± 1.00 pA, 506 
n = 8, p = 0.31, unpaired t-test) (Fig. 4B,E) in Cyfip1+/- PV+-IN compared to WT controls. We 507 
found, as measured by cell capacitance, that GCL PV+-IN were approximately 3 times larger 508 
than DGGC but that there was no difference in cell size between genotypes (WT: 31.8 ± 4.0 509 
pF, n = 6, Cyfip1+/-: 30.1 ± 1.87 pF, n = 8, p = 0.68, unpaired t-test) (Figure 4D). 510 
Consequently, when normalized to cell capacitance no difference in THIP evoked currents in 511 
WT ('ITHIP 3PM: 2.0 ± 0.4 pA/pF, n = 6;  'ITHIP 10PM: 5.4 ± 1.0 pA/pF, n = 6) compared to 512 
Cyfip1+/- ('ITHIP 3PM: 1.8 ± 0.2 pA/pF, n = 8, p = 0.80, 'ITHIP 10PM: 5.7 ± 0.4 pA/pF, n = 8, p = 513 
0.73, unpaired t-test) PV+-IN was observed. Thus, similarly to DGGC, haploinsufficiency of 514 
Cyfip1 does not significantly alter GABAergic inhibition in GCL PV+-IN of the mouse 515 
hippocampus.     516 
 517 
mRNA expression and protein levels of G and other key GABAA receptor subunits in 518 
hippocampus 519 
To confirm our electrophysiological findings, we first measured the expression level of the 520 
GABAAR G-subunit (encoded by Gabrd) in adult WT and Cyfip1+/- mice. Using ISH 521 
techniques, we measured GABAAR G-subunit mRNA expression in three major subfields of 522 
the hippocampus including the dentate gyrus (CA1, CA3, DG) (Fig. 5A). We confirmed, as 523 
shown previously (Fritschy and Panzanelli, 2014, Milenkovic et al., 2013; Zheng et al., 2009; 524 
Pirker et al., 2000), that the majority of GABAAR G-subunit expression occurs in the DG with 525 
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little G-subunit expression in the CA1 and CA3 hippocampal subfields (Brain Region: F(2,30) = 526 
55.370, p = 0.0001, 2-way ANOVA; Post Hoc Dunnett’s test show DG v CA1 and DG v CA3 527 
were both p = 0.0001). Significantly, we observed no influence of Cyfip1 haploinsufficiency 528 
on GABAAR G-subunit mRNA expression and its distribution across the hippocampus 529 
(Genotype: F(1,30) = 1.656, p = 0.208; Genotype x Brain Region F(2,30) = 0.006, p = 0.994, 2-530 
way ANOVA). The lack of change in GABAAR G-subunit expression was confirmed by 531 
complementary qRT-PCR techniques performed in the whole hippocampus of adult WT and 532 
Cyfip1+/- mice (Gabrd exp: F(1,26) = 2.526, p = 0.124, 1-way ANOVA) (Fig. 5B).  533 
 We next measured the mRNA expression of GABAAR D4-subunits (Gabra4), which 534 
are co-expressed with G-subunits in the majority, if not all, eGABAAR in DGGC (Sun et al., 535 
2004; Chandra et al., 2006). Consistent with a lack of change in G-subunit expression, we 536 
found no significant difference in the D4-subunit expression in hippocampus of adult WT and 537 
Cyfip1+/- mice (Gabra4 exp: F(1,25) = 0.105, p = 0.749, 1-way ANOVA, 1 outlier removed) 538 
(Fig. 5B). This was in agreement with unaltered GABAergic inhibition in DGGC (Fig. 1 and 539 
2). Furthermore, we assessed the expression of GABAAR D1-subunits (Gabra1) in WT and 540 
Cyfip1+/- mice, since these subunits can also form high affinity GABAAR with G-subunits 541 
(Glykys et al., 2007; Karim et al., 2013) and are highly expressed in GCL PV+-IN (Milenkovic 542 
et al., 2013). In line with our electrophysiological observations (Fig. 3), which showed no 543 
difference in tonic inhibition in PV+-IN, we found no difference in D1-subunit expression in 544 
adult WT and Cyfip1+/- mice (Gabra1 exp: F(1,26) = 0.849, p = 0.365, 1-way ANOVA) (Fig. 545 
5B). 546 
 Lastly, to complement the majority of our electrophysiological work, which was 547 
conducted in adolescent rather than adult mice, we extended our analysis of GABAAR G-548 
subunit expression into adolescent WT and Cyfip1+/- mice. Our data confirmed that 549 
hipppocampal GABAAR G-subunit mRNA expression (Gabrd mRNA exp: F(1,18) = 0.545, p = 550 
0.470, 1-way ANOVA) (Fig. 5C) and protein levels were also unaffected by Cyfip1 551 
  21 
haploinsufficiency (Gabrd protein: F(1,15) = 0.221, p = 0.221, 1-way ANOVA) (Fig. 5D) in 552 
adolescent mice.  553 
 554 
Tonic inhibition in GCL PV+ interneurons involves D1-subunit containing eGABAARs  555 
Although we found no significant difference in THIP evoked currents in molecularly defined 556 
GCL PV+-IN between Cyfip1+/- and WT mice, our data demonstrates for the first time to our 557 
knowledge, the presence of functional tonic GABAergic inhibition in these GCL interneurons. 558 
Consequently, we decided to further characterise the tonic GABA currents in these 559 
interneurons and compare them with their neighbouring granule cells. Therefore, we first 560 
measured basal tonic current in both PV+-IN and DGGC in WT mice under our in vitro 561 
conditions using the GABA channel blocker PTX (100 PM). In DGGC, application of PTX 562 
produced a significant reduction in the holding current (Table 2) of 12 ± 2.5 pA (Fig. 6A,D) 563 
which was accompanied by a reduction in RMS-noise of 1.98 ± 0.33 pA (Fig. 6A,F). The 564 
tonic current we recorded under basal conditions in DGGC was similar to that previously 565 
reported for these cells (Nusser and Mody, 2002; Chandra et al., 2006; Wlodarczyk et al., 566 
2013). On the other hand, basal tonic currents in PV+-IN (34.9 ± 3.5 pA, n = 4) were 567 
approximately three fold greater than those we observed in DGGC (Table 2 and Figure 568 
6A,D). However, when normalised to cell capacitance the tonic current density was not 569 
significantly different in PV+-IN (1.21 ± 0.09 pA/pF, n = 4) compared to DGGC (1.45 ± 0.38 570 
pA/pF, n = 5, p = 0.61, unpaired t-test) (Fig. 6E). Interestingly, when the fraction of total 571 
GABAergic inhibition provided by tonic inhibition versus phasic IPSCs is compared between 572 
DGGC and PV+-IN we find remarkable similarity between the cell types. The mean total 573 
charge was calculated as the sum of the total charge provided by IPSCs (Table 1) plus the 574 
charge provided by tonic inhibition. For DGGC, IPSCs provided 6.7% of the total inhibitory 575 
charge (0.87 pC of 12.97 pC total charge) and for PV-INs IPSCs provided 6.1% of the total 576 
inhibitory charge (2.28 pC of 37.18 pC total charge). The similarity between these values 577 
and their similarity to the fraction of inhibitory charge provided by tonic inhibition in other cell 578 
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types (Brickley et al., 1996; Rossi et al., 2003; Cope et al., 2005) suggests that expression of 579 
eGABAAR might be regulated to constrain the ratio of tonic to phasic inhibition within fairly 580 
narrow bounds across both inhibitory and excitatory neurons and this might be critical for 581 
stability of neuronal input-output transformations (Pavlov et al., 2009).  582 
 So far, we have shown that GCL PV+-IN are regulated by tonic GABAergic inhibition, 583 
as evidenced by their sensitivity to PTX, and that the eGABAAR underlying this tonic 584 
inhibition contain GABAAR G-subunits as revealed by their sensitivity to the agonist THIP. 585 
However, previous histological experiments have shown that PV+-IN have high expression of 586 
D1 GABAAR subunits and weaker expression of D4-subunits which predominate in DGGC 587 
(Sun et al., 2004; Chandra et al., 2006; Milenkovic et al., 2013). It has previously been 588 
shown that D1 subunits can form receptors with G-subunits but that these receptors have a 589 
markedly lower affinity for GABA than D4 containing receptors (Karim et al., 2013). Therefore, 590 
we next compared how tonic inhibition in PV+-IN and DGGC is changed by alterations in the 591 
extracellular GABA concentration. To do this we applied the GABA transporter 1 (GAT-1) 592 
inhibitor NNC-711 (10 PM) along with 5 PM GABA to elevate the concentration of GABA in 593 
the extracellular environment. In both cell types, bath application of NNC-711/GABA 594 
significantly increased the holding current (Table 2 and Fig. 6B,D) and RMS-noise (Table 2 595 
and Fig 6B,F) compared to control demonstrating that tonic inhibition in PV+-IN, like DGGC, 596 
is regulated by the GABA concentration in the extracellular space. Interestingly, the increase 597 
in tonic current was significantly larger in DGGC compared to PV-INs (Fig. 6B,D-F) 598 
suggesting that the former express eGABAAR with higher affinity for GABA and are more 599 
sensitive to changes in extracellular GABA as would be expected for D4 containing receptors 600 
versus D1 containing ones (see Discussion).   601 
Consequently, we next directly tested whether GCL PV+-IN express eGABAAR 602 
containing D1-subunits using the D1 selective non-benzodiazepine drug zolpidem. It is 603 
already established in DGGC that, although it modulates phasic inhibition by prolonging 604 
IPSC time-constants, zolpidem does not modulate tonic inhibition due to its lack of effect at 605 
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D4 containing eGABAARs (Nusser and Mody, 2002). We confirmed that application of 0.5 PM 606 
zolpidem did not significantly change the holding current (ΔIhold ZOLP: -4.4 ± 3.1 pA) or 607 
RMS-noise (ΔRMS ZOLP: -0.86 ± 0.17 pA) in DGGC (Table 2 and Fig. 6C-F). On the other 608 
hand, we found that bath application of zolpidem to PV+-IN produced a significant increase in 609 
the holding current (ΔIhold ZOLP: 23.9 ± 3.8 pA) and RMS-noise (ΔRMS ZOLP: 1.61 ± 0.61 610 
pA) (Table 2 and Fig. 6C-F). Thus, we conclude that molecularly defined PV+-IN in the 611 
dentate gyrus GCL receive tonic GABAergic inhibition which is mediated by extrasynaptic 612 
GABAARs containing G- and D1-subunits.  613 
 614 
 615 
 616 
 617 
Discussion 618 
 619 
Haploinsufficiency of Cyfip1 does not alter GABAergic inhibition in dentate gyrus 620 
Loss of fragile X mental retardation protein (FMRP) causes Fragile X syndrome and is 621 
associated with disrupted GABA signalling throughout the brain involving both pre- and 622 
postsynaptic mechanisms (Deng et al, 2011; Kang et al, 2017; Sabanov et al., 2017). A key 623 
binding partner of FMRP, CYFIP1, is encoded by the CYFIP1 gene which is found at the 624 
15q11.2 locus in humans. CNVs at this locus have been shown to significantly increase risk 625 
of development of neuropsychiatric and neurodevelopmental disorders including 626 
schizophrenia, autism spectrum disorder and intellectual disability. In this study, we set out 627 
to test the hypothesis that loss of a single copy of the gene encoding the FMRP-interacting 628 
protein Cyfip1, in a mouse model that mimics human disorders, would result in disruption of 629 
GABAergic inhibition in the hippocampus. We focused in particular on tonic GABAergic 630 
inhibition because disruption of this form of inhibition, resulting from reduced expression of 631 
the eGABAAR specific G-subunit, has been previously demonstrated following loss of FMRP 632 
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in a model of FXS, the Fmr1 KO mouse (D’Hulst et al., 2006; Curia et al., 2009; Zhang et al., 633 
2017). Contrary to our original hypothesis however, and in contrast to findings from the FXS 634 
mouse, the results of our electrophysiological and histological experiments demonstrate that, 635 
in DGGC and GCL PV+-IN, loss of a single copy of the Cyfip1 gene is not sufficient to 636 
produce changes in either phasic or tonic GABAergic inhibition. However, we cannot rule out 637 
impaired GABAergic signalling in other subfields of the hippocampus (see later), or other 638 
brain regions, in this genetic model.  639 
In this study, we investigated GABAergic inhibition in the DG of adolescent and adult 640 
WT and Cyfip1+/- mice. While the age of the adolescent mice (5-7 weeks) used in the 641 
majority of our experiments broadly matches the age of onset of schizophrenia symptoms in 642 
humans (Jones et al., 2013) it is noteworthy that the underlying pathological causes of 643 
schizophrenia are neurodevelopmental and precede the presentation of symptoms, and 644 
diagnosis, by many years. Moreover, Cyfip1 is a risk factor for both ASD and ID which are 645 
typically diagnosed in humans at a much younger juvenile age (Jones et al., 2013). Whilst 646 
we did not investigate GABAergic inhibition earlier in postnatal development, our results 647 
show a lack of functional change in GABAergic inhibition in Cyfip1 haploinsufficient 648 
adolescent mice that is in marked contrast to the effects seen in juvenile (Olmos-Serrano, 649 
2010, Sabanov 2017), adolescent/young adult (Curia et al 2009) and adult (Centonze et al 650 
2008) mice with the complete loss of Fmr1. Our original hypothesis was that the convergent 651 
function of Cyfip1 and Fmr1, through direct Cyfip1-FMRP interaction (Napoli et al., 2008), 652 
would regulate the translation of GABAAR signalling components (D’Hulst 2006) and 653 
therefore influence inhibitory GABAergic function (Sabanov 2015). Clearly, based on our 654 
new findings, this is not the case in the dentate gyrus. Further, the disparate phenotypes 655 
observed in GABAergic inhibition in Cyfip1 and Fmr1 KO animal models of genetic 656 
psychiatric risk may simply relate to differing gene dosage (single copy loss of Cyfip1 vs 657 
complete loss of Fmr1) and the subsequent levels of severity this has on the stoichiometry 658 
and/or function of the critically involved Cyfip1-Fmr1 complex. Thus, our findings suggest 659 
that either the interaction of CYFIP1 with FMRP is not critical in the ability of the latter to 660 
  25 
regulate eGABAAR expression or that a single copy of Cyfip1 is sufficient to allow high 661 
enough protein expression to permit normal FMRP function. In the context of human 662 
pathology, this is of critical significance since CNVs at the 15q11.2 locus never result in 663 
CYFIP1 homozygosity and in mice, Cyfip1 homozygosity is embryonically lethal. Thus, we 664 
conclude that disrupted tonic GABAergic inhibition in the dentate gyrus is unlikely to be a 665 
major contributor to the pathology of 15q11.2 CNV related disorders.  666 
It should be noted that FMRP target mRNAs are thought to consist of 842 mRNAs 667 
that bind to FMRP, as part of a FMRP messenger ribonucleoprotein (mRNP) complex, in the 668 
mouse forebrain (Darnell et al. 2011). However, three separate studies have each found 669 
diverse FMRP target datasets that only partially overlap with Darnell’s FMRP mRNA targets 670 
(Ascano et al, 2012; Myashiro et al., 2003; Brown et al., 2001). FMRP, in concert with CYFIP 671 
and as part of the functional FMRP-CYFIP1-eIF4E complex, represses protein translation of 672 
some of the FMRP target mRNAs (Napoli et al., 2008, Panja et al., 2014., Santini et al., 673 
2017). Furthermore, Cyfip1 and FMRP proteins are known to form other neurobiological 674 
complexes and therefore partake in a range of distinctive functions. For instance, Cyfip1 675 
forms part of the WAVE complex to regulate cytoskeletal dynamics (Schenck, et al, 2001) 676 
and FMRP is a key hub protein, involved in chromatin and ion channel binding, for instance 677 
(Davis & Broadie 2017) and so it might not be necessarily expected that phenotypes 678 
(including GABAergic signalling) of both models might closely map onto each other.  679 
A critical feature of the dentate gyrus is that it is one of only a few brain regions 680 
where new neurons are generated during adulthood. This process of neurogenesis, during 681 
which new DGGC are produced, takes place in the subgranular zone and granule cell layer 682 
and is heavily modulated by GABAergic inhibition (Aimone et al., 2014). In particular, PV+-IN 683 
play an important role in the control of cellular proliferation and migration by release of 684 
GABA onto both neural progenitor cells (NPCs) and their progeny, new born DGGC (Aimone 685 
et al., 2014; Song et al., 2012). It is therefore possible that more subtle or specific effects of 686 
the loss of Cyfip1 may have a disruptive effect on GABAergic modulation of NPCs or 687 
immature DGGC and thus impact on the neurogenic process although this remains to be 688 
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investigated. Moreover, tonic inhibition mediated by G-subunit containing eGABAAR is not 689 
restricted to the dentate gyrus of the hippocampus but plays a critical role in controlling 690 
cellular excitability in other hippocampal subfields and brain regions including the thalamus, 691 
cortex, cerebellum and striatum. In fact, Kittler and colleagues (2019) have recently 692 
examined the effect of complete Cyfip1 knock-out and GABA signalling in the CA1. 693 
Forebrain-specific Cyfip1 knock-out mice were shown to have increased mIPSCs in CA1 694 
pyramidal cells, with an overall change in excitatory and inhibitory (E/I) balance. Intriguingly, 695 
the opposite effect was shown when Cyfip1 was overexpressed in cultured hippocampal 696 
neurons with decreased mIPSC amplitude, increased mEPSC frequency and an overall 697 
increase in E/I balance. Differences between our findings and those of Kittler might 698 
genuinely reflect pleiotropic effects of reduced Cyfip1 dosage across different hippocampal 699 
subfields (DG vs CA1). It should also be noted that Kittler’s findings derive from both the 700 
complete loss and in vitro overexpression of Cyfip1, whilst our data derives from the 701 
constitutive Cyfip1 haploinsufficient mouse, modelling a CNV deletion that confers increased 702 
risk to a range of psychiatric disorders. 703 
Tonic inhibition in granule cell layer PV+ interneurons 704 
We found a lack of any genotype dependent functional difference in GABAergic signalling 705 
between WT and Cyfip1+/- mice in GCL PV+ interneurons. Our results do not rule out the 706 
possibility of genotype dependent differences in the expression of GABAAR subunits 707 
specifically in PV+-INs but do strongly suggest that any potential differences do not translate 708 
to deficits in functional inhibition in Cyfip1 haploinsufficient mice. Future studies, perhaps 709 
using single-cell RT-PCR or RNAseq techniques may provide further insight into the exact 710 
GABAAR subunit make-up in these cells following disruption of Cyfip1. However, despite the 711 
lack of functional effects of Cyfip1 on tonic GABAergic inhibition in GCL PV+-IN, our 712 
experiments have demonstrated, for the first time to our knowledge, that i) PV+-IN in the 713 
GCL express functional eGABAAR, ii) that these receptors incorporate G subunits and that iii) 714 
at least a proportion of the tonic inhibition in these cells is likely to be mediated through 715 
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eGABAAR containing D1 subunits. Several lines of evidence lead us to these conclusions. In 716 
GCL PV+-IN, we found that the increase in tonic GABA current, when the concentration of 717 
extracellular GABA was raised by adding GABA to the bath along with the GAT-1 blocker 718 
NNC711, was less than that observed in DGGC. Previously, Milenkovic et al. (2013) found 719 
ubiquitous expression GABAAR G subunits, high D1 and low D4 GABAAR subunit expression 720 
and strong co-localization of D1, β2 and G subunits in GCL PV+-IN. This data strongly 721 
suggested that these interneurons express D1/G eGABAAR as has been described previously 722 
for interneurons of the molecular layer (ML) of the dentate gyrus (Glykys et al., 2007). In the 723 
Xenopus oocyte expression system it has been shown that D1β3G GABAAR have a markedly 724 
lower affinity for GABA (EC50: 8.7 PM, Karim et al., 2012; EC50: 8.5 PM, Kaur et al., 2009) 725 
than D4β2G containing GABAAR (EC50: 1 PM, Karim et al., 2012; EC50: 0.41PM, Wongsamitkul 726 
et al., 2016) but that both of these G subunit containing GABAAR display properties of 727 
constitutive activity (Karim et al., 2012). This latter finding has been confirmed in rat DGGC 728 
where tonic currents at resting extracellular GABA levels appear to be largely mediated by G 729 
subunit containing GABAAR displaying GABA-independent channel openings (Wlodarczyk et 730 
al., 2013). Moreover, in mammalian expression systems, when GABA is used as the agonist, 731 
D1β3G and D4β2G GABAAR have been shown to have similar single channel conductances 732 
(Fisher and MacDonald, 1997; Keramidas and Harrison, 2008) and in DGGC expressing 733 
D4β2G receptors GABA-independent single channel currents are equivalent size to those in 734 
the presence of GABA (Wlodarczyk et al., 2013). Thus, based on our finding of similar 735 
normalized basal tonic currents in DGGC (1.4 ± 0.4 pA/pF) and PV+-IN (1.2 ± 0.1 pA/pF) and 736 
the previously reported similarities in D4/G and D1/G  receptor single channel conductances, 737 
we suggest that these cells express roughly similar densities of D4 and D1 containing 738 
eGABAAR respectively. We propose that at resting extracellular GABA levels, tonic currents 739 
in both DGGC and PV+-IN are mediated by constitutive activity relying largely upon GABA 740 
independent channel openings. This conclusion stems from the fact that the ambient level of 741 
extracellular GABA in the DG has been shown to be sufficiently low to indicate that the 742 
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majority of tonic inhibition in DGGC, which is mediated by higher affinity D4β2G, is via GABA-743 
independent channel openings (Wlodarczyk et al., 2013). Thus, at low basal ambient GABA 744 
levels, where a reasonably large tonic current is observed in PV+-IN, it is unlikely that lower 745 
affinity D1βXG eGABAAR would be strongly activated by the neurotransmitter while higher 746 
affinity D4β2G receptors in DGGC are not. However, as the extracellular GABA concentration 747 
is elevated, the differential expression of eGABAAR with substantially different GABA 748 
affinities (D4β2G >> D1βXG) between the two type of cells means that tonic currents are more 749 
strongly enhanced in DGGC compared to PV+-IN (i.e. the concentration response curve for 750 
GABA is significantly left-shifted in DGGC versus PV+-IN). It is unclear precisely what the 751 
physiological function of this difference in eGABAAR composition is. One possibility is that 752 
lower sensitivity to GABA in fast-spiking PV+-IN might permit these cells to elevate the level 753 
of extracellular GABA in the GCL, via perisomatic release of GABA, to a point where it can 754 
effectively enhance tonic inhibition to DGGC and reduce their firing without producing 755 
substantial tonic inhibitory feedback onto themselves or other PV+-IN that are in close 756 
physical proximity in the GCL. This could allow PV+-IN to respond to strong excitation by 757 
providing substantial feedforward inhibition to DGGC. On the other hand, PV+-IN in the GCL 758 
have dense axonal projections in the GCL itself and are typically peri-soma-inhibiting cells 759 
(Hu et al., 2014). Whereas, the expression of D4 and G subunits, and therefore D4β2G 760 
eGABAAR, in DGGC is greatest in their dendrites in the ML, the strongest expression of D1 761 
and G subunits in GCL PV+-IN is at the soma (Milenkovic et al., 2013). Thus, by expressing 762 
lower affinity somatic eGABAAR, when PV+-IN fire strongly, as happens for example during 763 
J-oscillations, they can provide robust temporally precise synaptic inhibition to the soma of 764 
nearby DGGC (Strüber et al., 2015; 2017), without the resulting GABA spill-over impacting 765 
substantially upon their own firing allowing them to maintain precise control of the timing of 766 
DGGC firing. Nonetheless, the presence of eGABAAR, albeit lower affinity ones, in GCL PV+-767 
IN would still provide a valuable auto-inhibitory backstop to regulate their own output should 768 
the extracellular GABA concentration become sufficiently elevated.  769 
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 Our new findings reveal that tonic inhibition in GCL PV+-IN, unlike DGGC, is sensitive 770 
to the D1 selective drug zolpidem. Thus, it is highly likely that at least a fraction of the tonic 771 
inhibition in PV+-IN, unlike DGGC, is mediated by receptors containing D1 subunits, possibly 772 
in arrangements containing G subunits or as DE pentamers. Although it is conventionally 773 
thought that zolpidem binding requires the presence of J-subunits that are not commonly 774 
found in eGABAARs, recent evidence has demonstrated a novel binding site for zolpidem at 775 
the interface between two D1 subunits (Che Has et al., 2016) further supporting the existence 776 
of D1EXG eGABAAR. Thus, PV+-IN may express distinct populations of eGABAAR with unique 777 
pharmacological properties that would allow them to be targets for new subunit selective 778 
GABA modulating drugs. These receptors might represent novel targets for treatment of 779 
neurodevelopmental and neuropsychiatric disorders where PV+-IN have long been 780 
implicated in disease (Lewis et al 2012; Nakazawa 2012).  781 
 782 
 783 
 784 
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Table 1. IPSC properties in DGGC and PV+-IN of WT and Cyfip1+/- mice (n = number of 988 
neurons from a minimum of 3 mice per genotype).  989 
 n Peak amplitude 
(pA) 
Weighted decay 
(ms) 
Frequency 
(Hz) 
Charge 
transfer (fC) 
Total IPSC 
Charge (pC) 
DGGC       
WT 25 29.5 ± 1.8 4.4 ± 0.1 6.3 ± 0.4 128.8 ± 8.3 0.87 ± 0.1 
Cyfip1+/- 14 29.7 ± 2.2 4.3 ± 0.1 5.9 ± 0.5 127.9 ± 10.3 0.76 ± 0.1 
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PVIN       
WT 18 44.9 ± 4.2 1.8 ± 0.2 25.1 ± 2.1 82.2 ± 11.5 2.28 ± 0.5 
Cyfip1+/- 13 44.0 ± 4.0 2.0 ± 0.2 27.9 ± 2.4 87.8 ± 9.9 2.54 ± 0.4 
       
 
 
 
      
Table 2. Pharmacologically induced changes in holding current in DGGC and PV+-IN (n = 990 
number of neurons from a minimum of 3 mice per genotype). 991 
Basal tonic GABA current 
 n Ihold control (pA) Ihold PTX (pA) RMS control (pA) RMS PTX (pA) 
DGGC 5 -68.4 ± 9.7 -56.3 ± 8.3 ** 5.2 ± 0.4 3.2 ± 0.2 ** 
PVIN 4 -85.9 ± 8.6 -51.1 ± 9.8 ** 7.6 ± 0.8  5.0 ± 0.8 * 
NNC and GABA evoked current 
 n Ihold control (pA) Ihold NNC/GABA (pA) RMS control (pA) RMS NNC/GABA (pA) 
DGGC 12 -67.2 ± 3.9 -140.3 ± 11.5 **** 4.6 ± 0.1 12.6 ± 0.8 **** 
PVIN 11 -147.8 ± 20.8  193.4 ± 21.1*** 8.1 ± 0.7 11.7 ± 0.7 **** 
Tonic GABA current in NNC and GABA 
 n Ihold NNC/GABA (pA) Ihold PTX  (pA) RMS NNC/GABA (pA) RMS PTX (pA) 
DGGC 6 -155.7 ± 20.7 -59.2 ± 6.9 ** 13.2 ± 1.5 3.6 ± 0.8 ** 
PVIN 4 -148.6 ± 23.6 -54.5 ± 14.8 ** 14.2 ± 1.0 6.1 ± 0.2 ** 
Zolpidem evoked current 
 n Ihold NNC/GABA (pA) Ihold ZOLP  (pA) RMS NNC/GABA (pA) RMS ZOLP (pA) 
DGGC 6 -118.0 ± 8.9 -113.7 ± 7.1 11.8 ± 0.7 11.0 ± 0.7 ** 
PVIN 7 -205.6 ± 30.2 -229.4 ± 28.6 ***  10.2 ± 0.4 11.8 ± 0.7 * 
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 993 
 994 
 995 
 996 
 997 
Figure 1. IPSCs in dentate gyrus granule cells of WT and Cyfip1+/- mice. (A) Dodt gradient 998 
contrast image of a horizontal section of the hippocampus. Dashed lines illustrate the border 999 
between the molecular layer (ML), granule cell layer (GCL) and subgranular zone (SGZ). 1000 
Patch pipette filled with Alexa Fluor 594 (left) illustrates the position of a mature DGGC 1001 
(right), imaged by 2-photon microscopy, with dendrites projecting to the edge of the ML. (B) 1002 
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Traces depicting typical electrophysiological properties of a mature DGGC. (C) A typical 1003 
voltage clamp recording showing IPSCs from DGGC of WT mouse and the averaged IPSC 1004 
from this cell. Inset schematic shown here and elsewhere signifies data recorded DGGC. (D) 1005 
A typical voltage clamp recording showing IPSCs from DGGC of Cyfip1+/- mouse and the 1006 
mean IPSC from this cell. (E) Histograms showing the mean (red/blue lines) and standard 1007 
deviation (light blue/red shading) of the log–normal distribution of all IPSC amplitudes 1008 
recorded in WT and Cyfip1+/- DGGC. Scatter plot shows the amplitude of individual IPSCs 1009 
group by cell, mouse and genotype. Individual IPSCs from each cell are shown as aligned 1010 
dots (light blue/red) with the mean IPSC amplitude for each cell shown as an unfilled 1011 
superimposed square (red/blue). Varying length vertical lines (blue/red) represent the mean 1012 
IPSC amplitude for each animal with the length of the bar illustrating the number of recorded 1013 
neurons from each mouse. Red/blue symbols (top) are the arithmetic mean and standard 1014 
deviation of the complete dataset for each genotype. (F) As in E but for log-transformed 1015 
IPSC amplitude data. (G) As in E but for IPSC instantaneous frequency data. (H) As in E but 1016 
for log-transformed IPSC frequency data. 1017 
 1018 
Figure 2. THIP evoked currents in DGGC of WT and Cyfip1+/- mice. (A) Trace showing PTX 1019 
sensitive concentration-dependent THIP evoked currents in a DGGC from a WT mouse. All-1020 
points histogram illustrates the shift in holding current and RMS-noise induced by THIP and 1021 
PTX. (B) As in A for DGGC in Cyfip1+/- mouse. (C) Scatter plot summarising the THIP-1022 
evoked currents in WT (blue) and Cyfip1+/- DGGC. (D) Scatter plot summarising membrane 1023 
capacitance of WT (blue) and Cyfip1+/- DGGC. (E) Scatter plot summarising the THIP-1024 
evoked changes in RMS-noise in WT (blue) and Cyfip1+/- DGGC. (F) Scatter plot 1025 
summarising the normalised (pA/PF) THIP-evoked current in WT (blue) and Cyfip1+/- DGGC. 1026 
 1027 
Figure 3. IPSCs in granule cell layer PV+-IN of WT and Cyfip1+/- mice. (A) Dodt gradient 1028 
contrast image of a horizontal section of the hippocampus. Dashed lines illustrate the border 1029 
between the molecular layer (ML), granule cell layer (GCL) and subgranular zone (SGZ). An 1030 
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example PV+-IN in the dentate gyrus granule cell layer identified by expression of the red 1031 
fluorescent protein tdTomato filled via the recording electrode with Alexa Fluor 488 (right) (B) 1032 
Traces depicting typical electrophysiological properties of a GCL PV+-IN. Inset shows the 1033 
shorter half-width of a typical PV+-IN action potential compared to that of a typical DGGC (C) 1034 
Voltage clamp recording showing IPSCs from PV+-IN of WT mouse and the averaged IPSC 1035 
from this cell. Inset schematic shown here and elsewhere signifies data recorded PV+-IN. (D) 1036 
A typical voltage clamp recording showing IPSCs from PV+-IN of Cyfip1+/- mouse and the 1037 
mean IPSC from this cell. (E) Histograms showing the mean (red/blue lines) and standard 1038 
deviation (light blue/red shading) of the log –normal distribution of all IPSC amplitudes 1039 
recorded in WT and Cyfip1+/-  PV+-IN. Scatter plot shows the amplitude of individual IPSCs 1040 
group by cell, mouse and genotype. Individual IPSCs from each cell are shown as aligned 1041 
dots (light blue/red) with the mean IPSC amplitude for each cell shown as an unfilled 1042 
superimposed square (red/blue). Varying length vertical lines (blue/red) represent the mean 1043 
IPSC amplitude for each animal with the length of the bar illustrating the number of recorded 1044 
neurons from each mouse. Red/blue symbols (top) are the arithmetic mean and standard 1045 
deviation of the complete dataset for each genotype. (F) As in E but for log-transformed 1046 
IPSC amplitude data. (G) As in E but for IPSC instantaneous frequency data. (H) As in E but 1047 
for log-transformed IPSC frequency data. 1048 
 1049 
Figure 4. THIP evoked currents in PV+-IN of WT and Cyfip1+/- mice. (A) Trace showing PTX 1050 
sensitive concentration-dependent THIP evoked currents in a PV+-IN from a WT mouse. All-1051 
points histogram illustrates the shift in holding current and RMS-noise induced by THIP and 1052 
PTX. (B) As in A for PV+-IN in Cyfip1+/- mouse. (C) Scatter plot summarising the THIP-1053 
evoked currents in WT (blue) and Cyfip1+/- PV+-IN. (D) Scatter plot summarising membrane 1054 
capacitance of WT (blue) and Cyfip1+/- PV+-IN. (E) Scatter plot summarising the THIP-1055 
evoked changes in RMS-noise in WT (blue) and Cyfip1+/- DGGC. (F) Scatter plot 1056 
summarising the normalised (pA/PF) THIP-evoked current in WT (blue) and Cyfip1+/- DGGC. 1057 
 1058 
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Figure 5. Molecular assessment of G and other key GABAA subunits in WT and Cyfip1+/- 1059 
mice. (A) mRNA expression of G GABAA subunit (Gabrd) in hippocampal subfields (CA1, 1060 
CA3, DG) of WT and Cyfip1+/-adult mice were measured by ISH and given as absolute mean 1061 
optical density values ± SEM (n = 6 per genotype). Once ANOVA revealed a main effect for 1062 
brain region, Dunnett’s test was used for post hoc analysis to determine the sources of 1063 
significance (DG vs CA1 and DG vs CA3, *** = P < 0.0001). Representative autoradiographs 1064 
shows two coronal WT mouse brain sections hybridised with an oligonucleotide probe 1065 
targeting Gabrd. (B) Expression of GABAA G, D4 and D1 subunits (equivalent to Gabrd, 1066 
Gabra4 and Gabra1 genes) were measured by quantitative real-time PCR mRNA expression 1067 
in adult whole hippocampus and given as mean delta Ct values ± SD relative to two 1068 
housekeeping genes, Gapdh and Hprt (n = 14 per genotype, 1 outlier removed in Gabra4 1069 
data). (C) As in B, qRT-PCR was used to measure Gabrd mRNA expression in juvenile WT 1070 
and Cyfip1+/- mice (n = 10 per genotype). (D) Hippocampal protein levels of G GABAA were 1071 
measured by immunofluorescent western blotting in WT and Cyfip1+/- mice. Cyfip1+/- 1072 
densitometric data given relative to the average of all WT samples (100%) and normalised to 1073 
protein loading control, Calnexin (WT: n = 9, Cyfip1+/-: n = 8). Representative 1074 
immunofluorescent blot shows Gabrd and Calnexin bands in WT and Cyfip1+/-mouse 1075 
samples.  1076 
 1077 
Figure 6. Tonic inhibition in PV+-IN is sensitive to extracellular GABA concentration and 1078 
modulated by the D1 selective ligand zolpidem. (A) Example traces showing the 1079 
approximately 3-fold larger basal tonic GABA current in PV+-IN compared to DGGC revealed 1080 
by application of the GABAA antagonist PTX. (B) Example traces showing the modulation of 1081 
tonic inhibition in PV+-IN and DGGC by the elevation of extracellular GABA concentration 1082 
using NNC711 (10 PM) and GABA (5 PM). (C) Example traces showing the modulation of 1083 
tonic inhibition in PV+-IN, but not DGGC, by the D1 selective ligand zolpidem. (D) Scatter 1084 
plots summarising the changes in holding current (ΔIhold) in DGGC and PV+-IN reflecting the 1085 
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basal tonic GABAergic inhibition, the current induced by NNC/GABA, the tonic GABA current 1086 
in NNC/GABA and the current induced by zolpidem. (E) As in D for normalised currents 1087 
(pA/pF). (F) As in D for changes in RMS-noise. 1088 
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